Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan S F Chan

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Vaccine|March 8, 2017
Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodiesJanie Parrino, Shelly A McNeil, Steven J Lawrence, et al.
The Pediatric Infectious Disease Journal|June 22, 2002
Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infectionShu Li, Ivan S F Chan, Holly Matthews, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zosterRichard Mills, Stephen K Tyring, Myron J Levin, et al.
Human Vaccines|November 4, 2011
Safety and tolerability of zoster vaccine in adults ≥60 years oldAlexander V Murray, Keith S Reisinger, Boris Kerzner, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 31, 2002
Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failureSandra L Watkins, Steven R Alexander, Eileen D Brewer, et al.
The Journal of Infectious Diseases|February 23, 2010
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responsesAdriana Weinberg, Ann A Lazar, Gary O Zerbe, et al.
The Clinical Journal of Pain|June 19, 2007
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adultsKenneth E Schmader, Richard Sloane, Carl Pieper, et al.
Vaccine|January 18, 2007
Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of ageStephen K Tyring, Francisco Diaz-Mitoma, Larry G Padget, et al.
Vaccine|December 3, 2014
Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of ageXiaoming Li, Jane H Zhang, Robert F Betts, et al.
The Journal of Pain|September 1, 2004
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventoryPaul M Coplan, Kenneth Schmader, Alexander Nikas, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Vaccine|March 8, 2017
Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodiesJanie Parrino, Shelly A McNeil, Steven J Lawrence, et al.
The Pediatric Infectious Disease Journal|June 22, 2002
Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infectionShu Li, Ivan S F Chan, Holly Matthews, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zosterRichard Mills, Stephen K Tyring, Myron J Levin, et al.
Human Vaccines|November 4, 2011
Safety and tolerability of zoster vaccine in adults ≥60 years oldAlexander V Murray, Keith S Reisinger, Boris Kerzner, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 31, 2002
Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failureSandra L Watkins, Steven R Alexander, Eileen D Brewer, et al.
The Journal of Infectious Diseases|February 23, 2010
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responsesAdriana Weinberg, Ann A Lazar, Gary O Zerbe, et al.
The Clinical Journal of Pain|June 19, 2007
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adultsKenneth E Schmader, Richard Sloane, Carl Pieper, et al.
Vaccine|January 18, 2007
Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of ageStephen K Tyring, Francisco Diaz-Mitoma, Larry G Padget, et al.
Vaccine|December 3, 2014
Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of ageXiaoming Li, Jane H Zhang, Robert F Betts, et al.
The Journal of Pain|September 1, 2004
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventoryPaul M Coplan, Kenneth Schmader, Alexander Nikas, et al.
Pageof 5